Related Experiment Video
Updated: Aug 6, 2026
09:34
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
Lipid Nanoparticles: A New Frontier in Diabetes Treatment
Bhawna Sharma1,2, Anil Ahuja3, Alok Pratap Singh4
1Research Scholar, Dr. K. N. MODI University, Newai, Distt. Tonk, Rajasthan, India.
Drug Metabolism and Bioanalysis
|July 23, 2026
Summary
Lipid-based nanoparticles (LNPs) improve antidiabetic therapies by enhancing drug delivery and patient adherence. These advanced systems offer better efficacy and safety compared to traditional methods.
Area of Science:
- Nanotechnology and Pharmaceutical Sciences
- Drug Delivery Systems
- Metabolic Disorders Therapeutics
Background:
- Lipid-based Nanoparticles (LNPs) are emerging as advanced carriers for antidiabetic medications.
- Existing therapies face challenges in efficacy, safety, and patient compliance.
- Poorly soluble antidiabetic drugs require innovative delivery systems for improved bioavailability.
Purpose of the Study:
- To comprehensively review and evaluate various lipid-based nanoparticle platforms for antidiabetic drug delivery.
- To compare the structural characteristics, drug loading, release kinetics, and targeting potential of different LNP systems.
- To highlight the advantages of LNPs over conventional formulations in treating diabetes.
Main Methods:
- Systematic review of scientific literature on lipid-based nanoparticles for antidiabetic applications.
- Comparative analysis of Solid Lipid Nanoparticles (SLNs), Nanostructured Lipid Carriers (NLCs), liposomes, and nanoemulsions.
- Evaluation of physicochemical properties, pharmacokinetic profiles, and therapeutic outcomes.
Main Results:
- LNPs demonstrate superior biocompatibility, drug protection, and oral bioavailability for antidiabetic agents.
- SLNs offer stability and controlled release; NLCs enhance drug loading and flexibility.
- Liposomes provide versatile drug encapsulation, while nanoemulsions facilitate rapid absorption, leading to improved therapeutic outcomes and reduced side effects.
Conclusions:
- Lipid-based nanoparticles represent a transformative strategy in advancing antidiabetic drug delivery.
- These systems enhance therapeutic efficacy, safety, and patient adherence.
- Addressing manufacturing and regulatory challenges is crucial for future translational research and clinical application.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...